CalciMedica (CALC) Change in Account Payables (2019 - 2026)
CalciMedica's (CALC) quarterly Change in Account Payables came in at $514000.0 in Q1 2026, up 690.8% YoY from $64997.1 in Q1 2025, and up 1068.18% on a QoQ basis from $44000.0 in Q4 2025.
CalciMedica (CALC) Change in Account Payables (2019 - 2026) Analysis & Trends
CalciMedica (CALC) has 8 years of Change in Account Payables data on file, last reported at $514000.0 in Q1 2026.
- Quarterly Change in Account Payables rose 690.8% year-over-year to $514000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$239000.0 (down 162.08% YoY) and the FY2025 annual result came in at -$840000.0, down 239.77% from the prior year.
- Change in Account Payables rose to $514000.0 in Q1 2026, from $44000.0 in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $1.4 million in Q2 2022 to a low of -$1.5 million in Q3 2023.
- A 5-year average of -$12882.4 and a median of $47000.0 in 2023 frame the typical range for Change in Account Payables.
- Annual changes were most pronounced in 2022 — Change in Account Payables soared 1360.22% — and 2023, when it sank 1471.7%.
- Tracing CALC's Change in Account Payables over 5 years: stood at $126000.0 in 2022, then tumbled by 62.7% to $47000.0 in 2023, then soared by 929.79% to $484000.0 in 2024, then sank by 90.91% to $44000.0 in 2025, then surged by 1068.18% to $514000.0 in 2026.
- The last three Change in Account Payables figures came in at $514000.0 (Q1 2026), $44000.0 (Q4 2025), and -$796000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | CalciMedica | 9.80 Mn | -8.82 Mn | - | -627,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -627,000.00 |
| Jun 30, 2026 | -627,000.00 |
| Mar 31, 2026 | 514,000.00 |
| Mar 31, 2026 | 514,000.00 |
| Dec 31, 2025 | 44,000.00 |
| Dec 31, 2025 | 44,000.00 |
| Sep 30, 2025 | -796,000.00 |
| Sep 30, 2025 | -796,000.00 |
| Jun 30, 2025 | -1,000.00 |
| Jun 30, 2025 | -1,000.00 |
| Mar 31, 2025 | -87,000.00 |
| Mar 31, 2025 | -87,000.00 |
| Dec 31, 2024 | 484,000.00 |
| Dec 31, 2024 | 484,000.00 |
| Sep 30, 2024 | -609,000.00 |
| Sep 30, 2024 | -609,000.00 |
| Jun 30, 2024 | 597,000.00 |
| Jun 30, 2024 | 597,000.00 |
| Mar 31, 2024 | 129,000.00 |
| Mar 31, 2024 | 129,000.00 |